Amine Bensmaine

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 385 citations · Full text

Medicine, Hematology, Pharmacotherapy +11

Factors Predicting for Efficacy and Safety of Docetaxel in a Compassionate-Use Cohort of 825 Heavily Pretreated Advanced Breast Cancer Patients

Jérôme Alexandre, Pascal Bleuzen, Jacques Bonneterre et al. · Journal of Clinical Oncology · 2000 · 79 citations

Medicine, Oncology, Pharmacology +14

Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer

P Soulié, Amine Bensmaine, Cristina Garrino et al. · European Journal of Cancer · 1997 · 68 citations

Medicine, Gynecology, Oncology +9

Simultaneous chemoradiotherapy as salvage treatment in locoregional recurrences of squamous head and neck cancer

Daniel Gandía, P. Wibault, Thierry Guillot et al. · Head & Neck · 1993 · 53 citations

Medicine, Oncology, Radiation Oncology +11

First clinical (phase 1b/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

Sagar Lonial, Niels W.C.J. van de Donk, Rakesh Popat et al. · Journal of Clinical Oncology · 2019 · 49 citations

Medicine, Pharmacology, Pharmacotherapy +17